Roundtable: experts share their views on clinical trial transparency

October 9, 2018

As seen in Pharmaceutical Technology - Posted Oct. 9, 2018 - Original Article

May 9, 2018 | By Ellen Daniel | The accessibility of clinical trial data is an issue which divides opinion in the pharmaceutical industry. Nine experts offer their views on the importance of transparency and what can be done to improve it.


A study published by The BMJ in 2012 found that only 22% of clinical trial data covered by the FDAA is submitted within one year of completion. The opacity of clinical trial data means that the medical community often lacks access to a complete picture of a drug or device’s efficacy, safety and side-effects. 

Continued on International Pharmaceutical Technology

Previous Article
Why sponsors need a global view of clinical trial compliance
Why sponsors need a global view of clinical trial compliance

Next Article
Clinical Trial Sponsors Take Heed: Study Disclosure Rules Are Expanding
Clinical Trial Sponsors Take Heed: Study Disclosure Rules Are Expanding